236 related articles for article (PubMed ID: 35404996)
1. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau P; Touzeau C
Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
4. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies in Multiple Myeloma: Present and Future.
Lancman G; Sastow DL; Cho HJ; Jagannath S; Madduri D; Parekh SS; Richard S; Richter J; Sanchez L; Chari A
Blood Cancer Discov; 2021 Sep; 2(5):423-433. PubMed ID: 34661161
[TBL] [Abstract][Full Text] [Related]
6. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
7. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
[TBL] [Abstract][Full Text] [Related]
8. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
9. Antibody therapies for multiple myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
[No Abstract] [Full Text] [Related]
10. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
12. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
13. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Lee H; Neri P; Bahlis NJ
Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
[TBL] [Abstract][Full Text] [Related]
14. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
Tomita U; Ishimoto Y; Ri M; Kawase Y; Hizukuri Y; Maru C; Nanai K; Nakamura R; Nakayama M; Oguchi-Oshima K; Sumi H; Ohtsuka T; Iida S; Agatsuma T
Sci Rep; 2024 Mar; 14(1):5135. PubMed ID: 38429446
[TBL] [Abstract][Full Text] [Related]
15. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
[TBL] [Abstract][Full Text] [Related]
16. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
[TBL] [Abstract][Full Text] [Related]
17. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
18. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
19. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
20. Current use of bispecific antibodies to treat multiple myeloma.
Lee H; Neri P; Bahlis NJ
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]